financetom
Business
financetom
/
Business
/
Amazon MGM Studios Head Jen Salke to depart, internal memo says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Amazon MGM Studios Head Jen Salke to depart, internal memo says
Mar 27, 2025 8:01 PM

(Reuters) - Jen Salke, head of Amazon's ( AMZN ) MGM Studios, will step down from her role to start a new production entity, according to an internal memo sent to employees by Prime Video and Amazon MGM Studios head Mike Hopkins, as seen by Reuters.

Salke, a former NBC Entertainment president, was known at Amazon ( AMZN ) for championing ambitious projects - such as the globe-trotting spy thriller, "Citadel" - that did not always connect with Amazon Prime Video's domestic audience.

She helmed the combined entity that emerged when Amazon ( AMZN ) closed its $8.5 billion acquisition of MGM, the fabled moviemaker behind "Rocky" and James Bond film franchises.

Hopkins also said in his memo the studio will not be replacing her.

"We've decided to flatten our leadership structure a bit and not fill the head of studios role," he said.

"In line with Amazon's ( AMZN ) recent work to streamline reporting lines and accelerate decision making, we felt this was the best direction for our studio, which will now operate as distinct film and television studios."

Courtenay Valenti, head of film, and Vernon Sanders, head of TV, will now report directly to Hopkins, while Sue Kroll will continue to lead global marketing across both film and TV.

Salke has already signed a first-look deal across both film and TV with Amazon MGM Studios for her production entity, according to the memo.

Hopkins also referred to the changes in the studio behind shows such as "Lord of the Rings: The Rings of Power" and "Reacher".

"We will be taking a couple of weeks to have thoughtful conversations with Jen's directs and others to finalize the ideal long-term structure for the Amazon MGM Studios organization as a whole, and we'll have more to share on that work soon."

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved